Patent application number | Description | Published |
20080200382 | Novel use of AIM3 acting as a tumor suppressor - The present invention relates to novel uses of AIM3 acting as a tumor suppressor, and more particularly to methods for using an AIM3 protein or a nucleic acid encoding the protein to activate ATM or ATR and to treat ATM- or ATR-mediated diseases. The AIM3 protein according to the present invention interacts directly with ATM/ATR so as to activate ATM/ATR and proteins regulated by ATM/ATR. Also, the AIM3 protein upregulates tumor suppressor gene p53 and its target genes so as to not only inhibit the proliferation of cells but also to induce apoptosis. | 08-21-2008 |
20090156536 | AIMP2-DX2 Gene and SiRNA Targeting AIMP2-DX2 - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer. | 06-18-2009 |
20100041608 | METHOD FOR STIMULATING WOUND HEALING - The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43 having an amino acid sequence set forth in SEQ ID NO: 1 or functional equivalents thereof. The composition used in the method of the present invention can be efficiently utilized for the wound healing, since p43, an effective ingredient of the composition, has an excellent effect on the wound healing by its action including the induction of macrophage/monocyte and endothelial cell re-epithelization, proliferation of fibroblasts or angiogenesis. | 02-18-2010 |
20110117572 | Antibody Specific to the AIMP2-DX2 - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer | 05-19-2011 |
20110124582 | NOVEL POLYPEPTIDE HAVING ANTI-TUMOR ACTIVITY - The present invention relates to a novel polypeptide having anti-tumor activity through inducing apoptosis of endothelial cell and use thereof. More particularly, the present invention relates to a method for inducing apoptosis of endothelial cell, and for preventing or treating cancer, comprising administering to a subject in need thereof an effective amount of (a) an isolated polypeptide having the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 9; or (b) an isolated polynucleotide encoding the polypeptide of (a). | 05-26-2011 |
20110136119 | AIMP2-DX2 Gene and its Uses - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer | 06-09-2011 |
20110189195 | METHOD FOR CONTROLLING CANCER METASTASIS OR CANCER CELL MIGRATION BY MODULATING THE CELLULAR LEVEL OF LYSYL TRNA SYNTHETASE - The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intra-cellular metabolism related to 67LR. The interaction between KRS and 67LR can be used effectively in treating, preventing and/or diagnosing of various diseases or disorders related to the interaction. | 08-04-2011 |
20110250701 | NOVEL APPLICATION OF AIMP1 POLYPEPTIDE - The present invention relates to a novel use of AIMP1 polypeptide, more particularly to a composition for diagnosis of arthritis comprising an antibody against AIMP1, a kit for diagnosis comprising the same, a method for diagnosis of arthritis comprising: acquiring a specimen from a subject; and detecting AIMP1 polypeptide included in the specimen, and an antibody against the AIMP1 polypeptide for diagnosis of arthritis. The present invention provides a composition for diagnosis of arthritis including an antibody against AIMP1 polypeptide as a novel diagnosis marker of arthritis, a kit for diagnosis including the same, a method for diagnosis of arthritis comprising: acquiring a specimen from a subject; and detecting AIMP1 polypeptide included in the specimen, and an antibody against the AIMP1 polypeptide for diagnosis of arthritis. The composition, kit for diagnosis, method for diagnosis and antibody against the AIMP1 polypeptide may be used to diagnose arthritis early since they allow easy diagnosis of arthritis using a specimen from the patient. | 10-13-2011 |
20110256119 | NOVEL USES OF GRS PROTEINS OR FRAGMENTS THEREOF - The present invention is related to a anticancer composition comprising full length GRS protein or a fragment thereof, a nucleic acid encoding the GRS protein or a fragment thereof. Since the GRS proteins or fragments thereof have activity to induce apoptosis of cancer cell specifically, a composition comprising the GRS proteins or fragments thereof or a nucleic acid encoding thereof may be useful to treatment of cancer. | 10-20-2011 |
20120010141 | METHOD FOR STIMULATING WOUND HEALING - The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43 having an amino acid sequence set forth in SEQ ID NO: 1 or functional equivalents thereof. The composition used in the method of the present invention can be efficiently utilized for the wound healing, since p43, an effective ingredient of the composition, has an excellent effect on the wound healing by its action including the induction of macrophage/monocyte and endothelial cell re-epithelization, proliferation of fibroblasts or angiogenesis. | 01-12-2012 |
20120015383 | NOVEL DIAGNOSTIC MARKER FOR TYPE 1 DIABETES MELLITUS - The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample. | 01-19-2012 |
20120283300 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS - This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer. | 11-08-2012 |
20120322802 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF - The present invention relates to novel 2,4-pyrimidine derivatives and a use thereof, and more particularly, to pyrimidine derivatives which are effective for systemic lupus erythematosus, a composition for preventing and treating systemic lupus erythematosus comprising the same as an active ingredient and a method for screening the same. The present inventors found novel materials inhibiting surface translocation of gp96 by mimicking a function of AIMP1 which is a molecular anchor for an intracellular residence of gp96, and identified in vitro and in vivo activity of the materials for preventing and treating SLE by alleviating SLE plasma in autoimmune diseases. Therefore, the present invention provides a novel method for screening a therapeutic agent for SLE, and preventing or treating SLE using the mechanism. | 12-20-2012 |
20140142333 | NOVEL ANILINE DERIVATIVES AND USE THEREOF - Aniline derivatives for anticancer treatment including a compound of the Formula 1, or a derivative thereof, as an active ingredient, | 05-22-2014 |
20140220596 | METHOD FOR SCREENING AN AGENT PREVENTING OR TREATING CANCER USING GLYCYL-TRNA SYNTHETASE AND CADHERIN - The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer. | 08-07-2014 |
20140249045 | NOVEL USE OF LEUCYL TRNA SYNTHETASE - Provided is a method of screening for agents for preventing or treating mTORC1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells. | 09-04-2014 |
20150038531 | USE OF A NOVEL AMINOPYRIDINE DERIVATIVE TO PREVENT OR TREAT CANCER - An aminopyridine derivative of Formula 1 and a method of preventing or treating cancer using the same. Formula 1: | 02-05-2015 |